Gross Profit Analysis: Comparing Catalent, Inc. and Perrigo Company plc

Catalent vs. Perrigo: A Decade of Gross Profit Trends

__timestampCatalent, Inc.Perrigo Company plc
Wednesday, January 1, 20145986000001447700000
Thursday, January 1, 20156153000001712400000
Friday, January 1, 20165876000002051800000
Sunday, January 1, 20176546000001979500000
Monday, January 1, 20187526000001831500000
Tuesday, January 1, 20198051000001773300000
Wednesday, January 1, 20209833000001815200000
Friday, January 1, 202113520000001416200000
Saturday, January 1, 202216400000001455400000
Sunday, January 1, 202310600000001680400000
Monday, January 1, 2024953000000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Catalent, Inc. vs. Perrigo Company plc

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. Over the past decade, Catalent, Inc. and Perrigo Company plc have shown distinct trends in their gross profits. From 2014 to 2023, Catalent's gross profit surged by approximately 77%, peaking in 2022. This growth reflects Catalent's strategic expansions and innovations in drug delivery technologies. In contrast, Perrigo's gross profit exhibited a more stable trajectory, with a slight dip in 2021 but recovering by 2023. This stability underscores Perrigo's consistent market presence in consumer self-care products. Notably, the data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting. As these companies navigate the evolving pharmaceutical landscape, their financial strategies will be pivotal in shaping future growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025